Akanji et al. assessed the levels of IGF-2 in male Arab patients with chronic schizophrenia, who had been receiving a stable dose of oral antipsychotic medications, showing that serum IGF-2 levels were significantly increased in schizophrenia patients and the levels of IGF-2 were positively correlated with atherogenic lipoproteins [24]. The gene discussed is IGF2; the disease is schizophrenia.